HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Factor IX (PTC)

Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).

Also Known As:

PTC; Coagulation Factor IX; Blood Coagulation Factor IX; Factor IX Complex; Factor IX Fraction; Complex, Factor IX; Factor IX, Coagulation; Fraction, Factor IX; IX Complex, Factor; IX Fraction, Factor; IX, Coagulation Factor; Autoprothrombin II; Christmas Factor; Plasma Thromboplastin Component; Blood-coagulation factor IX

Networked: 4470 relevant articles (156 outcomes, 621 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Nikiforov, Yuri E: 43 articles (12/2015 - 01/2002)
2.	Miyauchi, Akira: 41 articles (11/2015 - 01/2003)
3.	High, Katherine A: 33 articles (03/2015 - 04/2002)
4.	Ito, Yasuhiro: 32 articles (03/2015 - 01/2004)
5.	Santoro, Massimo: 32 articles (01/2014 - 01/2002)
6.	Herzog, Roland W: 28 articles (11/2015 - 04/2002)
7.	Xing, Mingzhao: 28 articles (04/2015 - 03/2004)
8.	Tuttle, R Michael: 27 articles (12/2015 - 06/2002)
9.	Kobayashi, Kaoru: 27 articles (01/2015 - 01/2004)
10.	Miya, Akihiro: 27 articles (03/2014 - 01/2004)

Related Diseases

1.	Hemophilia B (Haemophilia B) 01/01/1993 - "This direct approach, which is based on computer-aided analysis of the whole coding, promoter and exon-flanking factor IX gene sequences, proved to be helpful for carrier detection and prenatal diagnosis in most hemophilia B families, including sporadic cases. " 10/01/2008 - "Investigation of factor IX (FIX) has benefited from excellent gene-deleted mouse models that recapitulate many of the features of human haemophilia B. " 10/01/2014 - "Hemophilia B management has improved considerably since the introduction of high-purity plasma-derived factor IX (pdFIX) products in the early 1990s. " 09/01/2013 - "The rapid clearance of factor IX (FIX) necessitates frequent intravenous administration to achieve effective prophylaxis for patients with hemophilia B. " 03/01/1992 - "The American Red Cross has developed an immunoaffinity chromatography method to purify human coagulation Factor IX to high levels of purity for therapeutic treatment of hemophilia B. "
2.	Neoplasm Metastasis (Metastasis) 01/01/2012 - "It is possible that some PTC-SCC patients without distant metastasis who undergo locally curative surgery can survive for a prolonged period and adjuvant therapies can be effective for local and distant recurrences." 04/01/2013 - "High frequency recurrence, distant metastasis and treatment resistance can be found in cases of PTC so early diagnosis and treatment are critical for improved prognosis and better survival rates. " 05/01/2002 - "Average MMP-1 expression (mean relative intensity units+/-SE) was significantly greater among PTC (1.97+/-0.15; p=0.004) and FTC (2.2+/-0.25; p=0.006) compared to benign lesions (1.30+/-0.15); but there was no relationship between MMP-1 expression and invasion, metastasis, or recurrence. " 12/01/2000 - "In patients with RET/PTC chimeras, a statistically not significant tendency towards younger age, lower recurrence rate, and improved survival was observed, despite increased incidence of lymph node metastasis. " 01/01/2013 - "Both partial and comprehensive superior mediastinal dissections are effective and safe for the treatment of mediastinal metastasis of PTC if appropriately designed."
3.	Neoplasms (Cancer) 07/29/2015 - "Recently, photothermal therapy (PTT) that utilizes photothermal conversion (PTC) agents to ablate cancer under near-infrared (NIR) irradiation has attracted a growing amount of attention because of its excellent therapeutic efficacy and improved target selectivity. " 04/01/2015 - "Adjusting for age and baseline scores, participants receiving PTC had significantly improved depression and improved gynecologic and cancer-specific concerns at 4 months compared with UC participants (all P < .05); significant differences in gynecologic and cancer-specific concerns (P < .05) were sustained at 9 months. " 06/01/2009 - "Cases of PTC with many MGCs have a significantly greater likelihood of extrathyroidal extension and greater tumor size than cases with few/no MGCs. " 06/15/1991 - "Thereafter, however, the number of pTc detected was significantly greater in eyes bearing progressively growing AC tumors than in SC tumor-injected eyes. " 07/01/2005 - "PTC is superior to total vascular exclusion except in patients with tumors that are large and deep seated, hypervascular, and/or abutting the hepatic veins or vena cava and in patients with increased right-sided heart pressures."
4.	Hemophilia A (Haemophilia) 07/01/1999 - "Since in most countries carrier detection is based on factor IX coagulant activity (FIX:C) assay, this study was designed to determine whether carriers' FIX:C values are dependent on the severity of haemophilia (mild, moderate or severe) or on the genetic anomaly in the family. " 08/10/1997 - "In the case of factor IX, we have produced a high-titer adenovirus vector capable of transducing gut epithelial cells resulting in synthesis of factor IX. The results of our in vitro studies indicate that gene transfer targeting gut epithelium as a new approach to hemophilia gene therapy is rational and merits in vivo studies in hemophilia animal models." 07/01/1995 - "Gene therapy is a potential treatment for hemophilia, wherein cells transduced with a normal factor IX gene could provide a continuous in vivo source of circulating factor IX. In this study, we examined the potential use of hematopoietic cells as a target for factor IX gene therapy. " 05/01/1953 - "[Studies on a new hemorrhagic diseases similar to hemophilia; plasma thromboplastin component deficiency]." 06/01/2015 - "In addition, recent advances in recombinant factor IX protein engineering have led some hemophilia treaters to reconsider the urgency of genetic cure. "
5.	Hemorrhage 11/01/2015 - "Factor Consumption for Prophylaxis and Treatment of Bleeding: Recombinant Factor Ix Fc Fusion Protein Compared With Conventional Recombinant Factor Ix." 10/01/2015 - "Utilisation of this method has the potential to reduce the morbidity and mortality burden associated with post-PTC haemorrhage by preventing bleeding from the liver access tract." 01/01/2015 - "Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates." 05/01/2014 - "The use of coagulation factor IX concentrate to prevent anticipated bleeding, as primary or secondary prophylaxis, has become a common and recommended practice in children. " 08/01/2013 - "DPC was frequently presented in CHD patients undergoing PTC and associated with increasing minor/minimal bleeding and longer hospital stay. "

Related Drugs and Biologics

1.	papillary Thyroid cancer
2.	Factor VIII (Coagulation Factor VIII)
3.	Antibodies
4.	prothrombin complex concentrates (PPSB)
5.	Antigens
6.	recombinant FVIIa (rFVIIa)
7.	Proteins (Proteins, Gene)
8.	Blood Coagulation Factors (Coagulation Factor)
9.	Messenger RNA (mRNA)
10.	Iodine

Related Therapies and Procedures

1.	Thyroidectomy
2.	Neck Dissection (Radical Neck Dissection)
3.	Intramuscular Injections
4.	Stents
5.	Lymph Node Excision (Lymph Node Dissection)